{"id":549071,"date":"2021-06-23T13:38:01","date_gmt":"2021-06-23T13:38:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=549071"},"modified":"2021-06-23T13:38:01","modified_gmt":"2021-06-23T13:38:01","slug":"mrna-vaccine-and-therapeutics-market-covid19-impact-analysis-size-share-trends-and-forecast-2021","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/mrna-vaccine-and-therapeutics-market-covid19-impact-analysis-size-share-trends-and-forecast-2021_549071.html","title":{"rendered":"mRNA Vaccine and Therapeutics market – COVID19 Impact Analysis, Size, Share, Trends and Forecast 2021"},"content":{"rendered":"
\"mRNA<\/a><\/div>\n
The global mRNA Vaccine and Therapeutics market gained a market size of nearly USD 587.5 million in 2020 and is estimated to reach 2911.8 million in 2027 with a CAGR of 28.4 % during the forecast period.<\/div>\n

The global mRNA Vaccine and Therapeutics market<\/a> gained a market size of nearly USD 587.5 million in 2020 and is estimated to reach 2911.8 million in 2027 with a CAGR of 28.4 % during the forecast period.<\/p>\n

Global mRNA Vaccine and Therapeutics Market, 2020 – 2027 (USD Million)<\/strong><\/p>\n

mRNA vaccines are the advanced type of vaccine designed to generate immunity against infectious diseases. Many vaccines use inactivated or weakened form of the pathogen to trigger the immune response in the body. However, mRNA vaccines program cell to make a protein or even just a part of a protein which can induce an immune response against pathogens. With the advanced research many biological drug manufacturers are focusing on producing mRNA vaccines owing to their high efficiency.<\/p>\n

Key Trends in Global Market<\/strong><\/p>\n

Increasing research on mRNA vaccines<\/strong><\/p>\n

mRNA vaccines are tested highly efficient for generating immune response in the human body. Also, the immunity generated by mRNA vaccines stays for long period of time. Owing to such advantages many bio-pharmaceutical companies are focusing on developing mRNA vaccines for deadly diseases. In addition, current COVID-19 pandemic also spurred the demand of mRNA vaccines and therapeutic. Many pharma majors such Pfizer-BioNTech and the Moderna have already developed mRNA vaccines for COVID-19, and many other market players are focusing to invest high amount for the development of mRNA-based vaccines.<\/p>\n

Browse the full report at<\/strong>  https:\/\/www.credenceresearch.com\/report\/mrna-vaccine-and-therapeutics-market<\/a><\/p>\n

Global Market by Vaccine Type Insights<\/strong><\/p>\n

mRNA vaccine and therapeutic are primarily categorized as self-amplifying mRNA-based vaccines and conventional non-amplifying mRNA-based vaccines in this market. Owing to high efficiency of self-amplifying mRNA-based vaccines over other types of mRNA vaccines demand for self-amplifying mRNA vaccines is more. Which is also mainly causing the large share of the segment in overall market.<\/p>\n

Global Market by Application Insights<\/strong><\/p>\n

Applications of mRNA vaccine and therapeutics are categorized as cancer, infectious disease, and other in the global market. infectious disease segment holds the largest share of the market owing to high prevalence of infectious disease worldwide. For instance, current COVID-19 pandemic has created huge demand for mRNA vaccine and therapeutic worldwide.<\/p>\n

Global Market by Regional Insights<\/strong><\/p>\n

North America is the largest market for mRNA vaccine and therapeutics. The region expected to remain major revenue contributor for mRNA vaccine and therapeutics market over the forecast period. Presence of major bio-pharma players, and high investments on research for development of mRNA vaccines is primarily contributing to the major share of the market in this region.<\/p>\n

Global Market Competitive Landscape<\/strong><\/p>\n

Some of the market players with a large share in the global market include Pfizer Inc., Arcturus Therapeutics Inc., Moderna Therapeutics Inc., BioNTech SE, CureVac AG, Etherna, ethris GmbH, Translate Bio Inc., GlaxoSmithKline PLC, Argos Therapeutics, Inc., Sangamo Therapeutics Inc. The report covers very detailed profiles of these key players.<\/p>\n

Market Segmentation<\/strong><\/p>\n

Global mRNA Vaccine and Therapeutics Market by Vaccine Type, 2015 – 2027<\/strong><\/p>\n

· Self-amplifying mRNA-based Vaccines<\/p>\n

· Conventional Non-Amplifying mRNA-Based Vaccines<\/p>\n

Global mRNA Vaccine and Therapeutics Market by Application, 2015 – 2027<\/strong><\/p>\n

· Cancer<\/p>\n

· Infectious Disease<\/p>\n

· Others<\/p>\n

Global mRNA Vaccine and Therapeutics Market by End User, 2015 – 2027<\/strong><\/p>\n

· Hospitals and Clinics<\/p>\n

· Research Organizations<\/p>\n

· Other End-User<\/p>\n

Global mRNA Vaccine and Therapeutics Market by Region, 2015 – 2027<\/strong><\/p>\n

· North America<\/p>\n

· Europe<\/p>\n

· Asia Pacific<\/p>\n

· Latin America<\/p>\n

· Middle East and Africa<\/p>\n

Global mRNA Vaccine and Therapeutics Market: Key Players<\/strong><\/p>\n

· Pfizer Inc.<\/p>\n

· Arcturus Therapeutics Inc.<\/p>\n

· Moderna Therapeutics Inc.<\/p>\n

· BioNTech SE<\/p>\n

· CureVac AG<\/p>\n

· Etherna<\/p>\n

· ethris GmbH<\/p>\n

· Translate Bio Inc.<\/p>\n

· GlaxoSmithKline PLC<\/p>\n

· Argos Therapeutics, Inc.<\/p>\n

· Sangamo Therapeutics Inc.<\/p>\n

Browse the full report at<\/strong>  https:\/\/www.credenceresearch.com\/report\/mrna-vaccine-and-therapeutics-market<\/a><\/p>\n

ToC:<\/strong><\/p>\n

Table of Content<\/strong>
1.Preface<\/strong>
1.1.Report Description
1.1.1.Purpose of the Report
1.1.2.Target Audience
1.1.3.USP and Key Offerings
1.2.Research Scope
1.3.Research Methodology
1.3.1.Phase I – Secondary Research
1.3.2.Phase II – Primary Research
1.3.3.Phase III – Expert Panel Review
1.3.4.Approach Adopted
1.3.4.1.Top-Down Approach
1.3.4.2.Bottom-Up Approach
1.3.5.Assumptions
1.4.Market Segmentation<\/p>\n

2.Executive Summary<\/strong>
2.1.Market Snapshot: Global mRNA Vaccine and Therapeutics Market<\/p>\n

3.Market Dynamics & Factors Analysis<\/strong>
3.1.Introduction
3.1.1. Global mRNA Vaccine and Therapeutics Market Value, 2015-2027, (US$ Mn)
3.2.Market Dynamics
3.2.1.Key Growth Trends
3.2.2.Major Industry Challenges
3.2.3.Key Growth Pockets
3.3.Attractive Investment Proposition,2020
3.3.1.Vaccine Type
3.3.2.Application
3.3.3.End User
3.3.4.Geography
3.4.Porter’s Five Forces Analysis
3.4.1.Threat of New Entrants
3.4.2.Bargaining Power of Buyers\/Consumers
3.4.3.Bargaining Power of Suppliers
3.4.4.Threat of Substitute Vaccine Types
3.4.5.Intensity of Competitive Rivalry
3.5.Value Chain Analysis<\/p>\n

4.Market Positioning of Key Players, 2020<\/strong>
4.1.Company market share of key players, 2020
4.2.Top 6 Players
4.3.Top 3 Players
4.4.Major Strategies Adopted by Key Players<\/p>\n

5.COVID 19 Impact Analysis<\/strong>
5.1.Global mRNA Vaccine and Therapeutics Market Pre Vs Post COVID 19, 2019 – 2027
5.2.Impact on Import & Export
5.3.Impact on Demand & Supply<\/p>\n

6.North America<\/strong>
6.1.North America mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
6.1.1.U.S.
6.1.2.Canada
6.1.3.Mexico
6.2.North America mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
6.2.1.Overview
6.2.2.Self-amplifying mRNA-based Vaccines
6.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
6.3.North America mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
6.3.1.Overview
6.3.2.Cancer
6.3.3.Infectious Disease
6.3.4.Other Applications
6.4.North America mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
6.4.1.Overview
6.4.2.Hospitals and Clinics
6.4.3.Research Organizations
6.4.4.Other End Users<\/p>\n

7.Europe<\/strong>
7.1.Europe mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
7.1.1.UK
7.1.2.France
7.1.3.Germany
7.1.4.Italy
7.1.5.Russia
7.1.6.Spain
7.1.7.Belgium
7.1.8.Netherland
7.1.9.Austria
7.1.10.Sweden
7.1.11.Poland
7.1.12.Denmark
7.1.13.Switzerland
7.1.14.Rest of Europe
7.2.Europe mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
7.2.1.Overview
7.2.2.Self-amplifying mRNA-based Vaccines
7.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
7.3.Europe mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
7.3.1.Overview
7.3.2.Cancer
7.3.3.Infectious Disease
7.3.4.Other Applications
7.4.Europe mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
7.4.1.Overview
7.4.2.Hospitals and Clinics
7.4.3.Research Organizations
7.4.4.Other End Users<\/p>\n

8.Asia Pacific<\/strong>
8.1.Asia Pacific mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
8.1.1.China
8.1.2.Japan
8.1.3.South Korea
8.1.4.India
8.1.5.Australia
8.1.6.New Zealand
8.1.7.Taiwan
8.1.8.Southeast Asia
8.1.9.Central Asia
8.1.10.Rest of Asia Pacific
8.2.Asia Pacific mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
8.2.1.Overview
8.2.2.Self-amplifying mRNA-based Vaccines
8.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
8.3.Asia Pacific mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
8.3.1.Overview
8.3.2.Cancer
8.3.3.Infectious Disease
8.3.4.Other Applications
8.4.Asia Pacific mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
8.4.1.Overview
8.4.2.Hospitals and Clinics
8.4.3.Research Organizations
8.4.4.Other End Users<\/p>\n

9.Latin America<\/strong>
9.1.Latin America mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
9.1.1.Brazil
9.1.2.Argentina
9.1.3.Peru
9.1.4.Chile
9.1.5.Colombia
9.1.6.Rest of Latin America
9.2.Latin America mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
9.2.1.Overview
9.2.2.Self-amplifying mRNA-based Vaccines
9.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
9.3.Latin America mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
9.3.1.Overview
9.3.2.Cancer
9.3.3.Infectious Disease
9.3.4.Other Applications
9.4.Latin America mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
9.4.1.Overview
9.4.2.Hospitals and Clinics
9.4.3.Research Organizations
9.4.4.Other End Users<\/p>\n

10.Middle East<\/strong>
10.1.Middle East mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
10.1.1.UAE
10.1.2.KSA
10.1.3.Israel
10.1.4.Turkey
10.1.5.Iran
10.1.6.Rest of Middle East
10.2.Middle East mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
10.2.1.Overview
10.2.2.Self-amplifying mRNA-based Vaccines
10.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
10.3.Middle East mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
10.3.1.Overview
10.3.2.Cancer
10.3.3.Infectious Disease
10.3.4.Other Applications
10.4.Middle East mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
10.4.1.Overview
10.4.2.Hospitals and Clinics
10.4.3.Research Organizations
10.4.4.Other End Users<\/p>\n

11.Africa<\/strong>
11.1.Africa mRNA Vaccine and Therapeutics Market, by Country, 2015-2027(US$ Mn)
11.1.1.South Africa
11.1.2.Egypt
11.1.3.Nigeria
11.1.4.Rest of Africa
11.2.Africa mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
11.2.1.Overview
11.2.2.Self-amplifying mRNA-based Vaccines
11.2.3.Conventional Non-Amplifying mRNA-Based Vaccines
11.3.Africa mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
11.3.1.Overview
11.3.2.Cancer
11.3.3.Infectious Disease
11.3.4.Other Applications
11.4.Africa mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
11.4.1.Overview
11.4.2.Hospitals and Clinics
11.4.3.Research Organizations
11.4.4.Other End Users<\/p>\n

12.Global<\/strong>
12.1.Global mRNA Vaccine and Therapeutics Market, by Vaccine Type, 2015-2027(US$ Mn)
12.1.1.Overview
12.1.2.Self-amplifying mRNA-based Vaccines
12.1.3.Conventional Non-Amplifying mRNA-Based Vaccines
12.2.Global mRNA Vaccine and Therapeutics Market, by Application, 2015-2027(US$ Mn)
12.2.1.Overview
12.2.2.Cancer
12.2.3.Infectious Disease
12.2.4.Other Applications
12.3.Global mRNA Vaccine and Therapeutics Market, by End User, 2015-2027(US$ Mn)
12.3.1.Overview
12.3.2.Hospitals and Clinics
12.3.3.Research Organizations
12.3.4.Other End Users<\/p>\n

13.Company Profiles<\/strong>
13.1.Pfizer Inc.
13.2.Arcturus Therapeutics Inc.
13.3.Moderna Therapeutics Inc
13.4.BioNTech SE
13.5.CureVac AG
13.6.Etherna
13.7.ethris GmbH
13.8.Translate Bio Inc.
13.9.GlaxoSmithKline PLC
13.10.Argos Therapeutics, Inc.
13.11.Sangamo Therapeutics Inc.<\/p>\n

Browse the full report at<\/strong>  https:\/\/www.credenceresearch.com\/report\/mrna-vaccine-and-therapeutics-market<\/a><\/p>\n

Related report: Foot and Mouth Disease (FMD) Vaccines Market<\/a> – Growth, Future Prospects, Competitive Analysis, 2018 – 2026<\/strong><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> Credence Research<\/a>
Contact Person:<\/strong> Chris Smith
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 18003618290
City:<\/strong> SAN JOSE
State:<\/strong> CA
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.credenceresearch.com\/report\/mrna-vaccine-and-therapeutics-market<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

The global mRNA Vaccine and Therapeutics market gained a market size of nearly USD 587.5 million in 2020 and is estimated to reach 2911.8 million in 2027 with a CAGR of 28.4 % during the forecast period. The global mRNA … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,403,404,416],"tags":[],"class_list":["post-549071","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/549071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=549071"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/549071\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=549071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=549071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=549071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}